Shares of BeyondAirInc . (NASDAQ:XAIR) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus price objective of $14.00 for the company and are anticipating that the company will post ($0.30) EPS for the current quarter, according to Zacks. Zacks has also given BeyondAirInc . an industry rank of 80 out of 256 based on the ratings given to its competitors.
XAIR traded up $0.03 on Friday, hitting $5.00. 6,520 shares of the company’s stock were exchanged, compared to its average volume of 14,001. The firm has a market cap of $54.58 million, a price-to-earnings ratio of -5.95 and a beta of -0.27. BeyondAirInc . has a twelve month low of $3.11 and a twelve month high of $6.25.
BeyondAirInc . Company Profile
Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.
Further Reading: What is the Coverage Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.